IAS Urges New Focus on ART as Prevention
4 November 2009 (Geneva, Switzerland) - The
International AIDS Society (IAS) today saluted the World
Health Organization (WHO) for its focus on scaling up
antiretroviral therapy (ART) as prevention as well as for
treatment. The WHO consultation that concluded today has
reaffirmed the urgent need for universal access to ART for
the treatment of people living with HIV, emphasizing the
clinical benefit of early treatment for individuals, as well
as the prevention impact of increased access to ART in
reducing HIV transmission and tuberculosis (TB) incidence.
The IAS's statement came at the end of a three-day
consultation on ART for HIV Prevention convened by
WHO.
ART significantly reduces HIV viral load, thereby
reducing the risk of HIV transmission. In high-income
countries, ART has virtually eliminated transmission of HIV
from mothers to their babies, and a number of studies
indicate that universal provision of ART to people living
with HIV would have a major impact on reducing HIV
transmission and TB incidence globally.
A recent
mathematical model by Granich et al (WHO, 2009) also has
proposed that universal, voluntary HIV testing on an annual
basis, immediately followed by ART for all persons who test
positive, would likely result in a 95 percent reduction in
annual HIV incidence globally within 10
years.
Importantly, the health benefits of universal
access to ART are not limited to reducing HIV illness and
transmission. Earlier initiation of ART has also been
associated with better survival, improved tolerability of
therapy, and improved immune response, and has been shown to
reduce the transmission of tuberculosis among HIV-infected
individuals.
"In addition to saving lives and
improving individual health, HIV therapy has tremendous
potential to improve health at the community level, by
reducing HIV transmission and the incidence of tuberculosis,
which continues to be a major killer in low- and
middle-income countries" said IAS President Dr. Julio
Montaner, Director of the BC Centre for Excellence in
Vancouver, Canada. "But the promise of ART, to save lives
and reduce millions of new HIV infections, will not be
fulfilled without immediate follow-through on the commitment
to universal access made by the G8 nations in 2005. That
commitment comes due in 2010, and we are still far from able
to reach all those in need of therapy quickly and
effectively."
The UN's most recent progress report on
universal access indicates that less than half of all people
living with HIV in the world who could benefit clinically
from ART have access. WHO treatment guidelines call for the
initiation of ART at a relatively late stage of HIV disease,
when an individual's immune system has already been weakened
substantially by the virus. These guidelines will change
soon, and new guidance is expected to urge earlier
initiation of ART.
Noting that demand for ART access,
and associated costs, will increase significantly as
programmes adopt the clinically sound CD4 threshold of 350
cells/mm3 as a starting point for ART, Montaner added that
"savings from reduced HIV transmission, increased wellbeing,
and decreased illnesses and hospitalizations make such a
move not only feasible but also fiscally sound. Our models
suggest that this can be a highly cost-effective
strategy."
The IAS specifically called for increased
operations research on the preventative benefits of more
widespread treatment scale up, including continued support
for the 2007 Sydney Declaration, which was adopted at the
4th IAS Conference on HIV Pathogenesis, Treatment and
Prevention. The declaration urges that 10 percent of all
resources dedicated to HIV programming from granting
agencies and national health budgets be allocated for
operations research to improve HIV interventions.
"At
every step along the way to universal access, the scale-up
of HIV treatment should be guided by operations research,"
said IAS Executive Director Robin Gorna. "Such research will
ensure that the implications of more widespread HIV testing
and treatment -- including its implications for equity,
human rights, morbidity and mortality, and the preventative
impact of ART on HIV transmission -- are informed by
evidence of what works
best."
ENDS